Sysmex America announces US FDA 510(k) clearance for the CellaVision DC-1, which automates and simplifies the process of performing blood cell differentials in low-volume hematology labs. Eliminating most manual steps traditionally done by lab technicians performing blood cell differentials maximizes speed and productivity, and the system’s standardized testing process helps reduce the negative impact of subjective interpretations and assessments. In addition, the device reduces review time for differentials, standardizes differential results by automating cell location and pre-classification, and enables input from across the organization through real-time collaboration and centrally stored images and comments.

Sysmex America